Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia

Nina Rise, Toke Touborg, Ditte Helene Lundsted, Michael Dalager-Pedersen, Trine H. Mogensen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

2 Citations (Scopus)
28 Downloads (Pure)

Abstract

Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA.

Original languageEnglish
Article number1057065
JournalFrontiers in Immunology
Volume13
DOIs
Publication statusPublished - 24 Nov 2022

Bibliographical note

Copyright © 2022 Rise, Touborg, Lundsted, Dalager-Pedersen and Mogensen.

Keywords

  • Adult
  • Agammaglobulinemia/complications
  • COVID-19
  • Disease Progression
  • Genetic Diseases, X-Linked/complications
  • Humans
  • Male
  • SARS-CoV-2
  • Bruton’s agammaglobulinemia
  • inborn error of immunity
  • viral Evolution
  • vaccination

Fingerprint

Dive into the research topics of 'Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton's agammaglobulinemia'. Together they form a unique fingerprint.

Cite this